MERS-CoV Spike RBD Antibody

Catalog #: MAB107073 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB107073-100
MAB107073-SP

Detection of MERS-CoV Spike protein bound to CD26 in HEK293 Human Cell Line Transfected with Human CD26 and eGFP by Flow Cytometry.

1 Image

All Spike RBD Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

MERS-CoV Spike RBD Antibody Summary

Species Reactivity

MERS-CoV

Specificity

Detects MERS-CoV Spike RBD in direct ELISAs.

Source

Monoclonal Mouse IgG_2A Clone # 1038345

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Chinese Hamster Ovary cell line CHO-derived MERS-CoV Spike RBD
Glu367-Tyr606
Accession # YP_007188579.1

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Flow Cytometry

0.25 µg/10⁶ cells

MERS-CoV Spike protein bound to CD26 in HEK293 Human Cell Line Transfected with Human CD26 and eGFP

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry

View Larger

Detection of MERS-CoV Spike protein bound to CD26 in HEK293 Human Cell Line Transfected with Human CD26 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with human CD26 and eGFP was incubated with Recombinant MERS-CoV Spike S1 Fc protein (10606-CV), then stained with (A) Mouse Anti-MERS-CoV-2 Spike Monoclonal Antibody (Catalog # MAB107073) or (B) Mouse IgG2A Isotype Control Antibody (MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B). Staining was performed using our Staining Membrane-associated Proteins protocol.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Spike RBD

MERS-CoV (also known as HCoV-EMC), which causes the Middle East Respiratory Syndrome (MERS), was first reported in Saudi Arabia in 2012 as a novel coronavirus (1). Coronaviruses are a family of viruses that are commonly comprised of a large plus-strand RNA genome and four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N). There are two well-known human coronavirus families that infect humans: Alpha coronaviruses which includes HCoV-229E and HCoV-NL63; beta coronaviruses that includes MERS-CoV, HCov-OC43, Severe Acute Respiratory Syndrome (SARS-CoV), and global pandemic Covid-19 (SARS-CoV2) (2). The MERS-CoV Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry, and it consists of two subunits, S1 and S2. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3). Located within the S1 subunit is the receptor binding domain (RBD). The RBD is responsible for the binding of MERS-CoV to dipeptidyl peptidase IV (DPP4, also known as human CD26) (4). The RBD of MERS-CoV shares 24% and 21% amino acid sequence (aa) identity with SARS-CoV RBD and SARS-Cov2 RBD, respectively. The low aa sequence identity is consistent with the finding that MERS-CoV and SARS-CoV bind different cellular receptors (4). The S1 subunit, especially the RBD region, of MERS-CoV was commonly targeted for vaccinations or antiviral therapies (5-7).

References

Zaki, A.M. et al. (2012) N. Engl. J. Med. 367:1814.
Ogimi, C. et al. (2020) J Pediatric Infect Dis Soc doi: 10.1093/jpids/piaa037.
Li, Y. et al. (2019) Engineering. 5:940.
Raj, V.S. et al. (2013) Nature 495:251.
Corti, D. et al. (2016) J. Infect. Public Health 9:231.
Tang, X.C. et al. (2014) Proc. Natl. Acad. Sci. USA 111:E2018.
Jiang, L. et al. (2014) Sci. Transl. Med. 6:234ra59.